ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside pipeline advances at CROI 2021
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced the presentation of 16 sponsored abstracts from its diverse portfolio of innovative pipeline and licensed HIV treatment and prevention options at the Conference on Retroviruses and Opportunistic Infections (CROI 2021), being held virtually 6-10 March.
Key data presentations will include:
- ATLAS-2M 96-week findings for investigational long-acting cabotegravir and rilpivirine administered every 2-months for the treatment of HIV-1 in virologically suppressed adults, which build upon earlier 48-week efficacy and safety data, as well as an analysis of renal and bone outcomes from ATLAS and ATLAS-2M.
- Phase IIa proof-of-concept findings for the maturation inhibitor GSK3640254 (GSK’254), a novel, investigational, antiretroviral agent with a new mechanism of action that is being studied in adults living with HIV-1.
- Pharmacokinetic (PK) and resistance data from HPTN 083,* a study of investigational cabotegravir every 2-months for HIV prevention from HPTN 083 in men who have sex with men (MSM) and transgender women (TGW).
Kimberly Smith, M.D., MPH, Head of Research & Development at ViiV Healthcare, said: “The innovation powered by our research and development team strives to redefine what is possible in both HIV treatment and prevention. The findings that will be presented at CROI 2021 reflect this goal, with new data that further establish our leadership in long-acting therapies for HIV treatment and prevention, as well as proof-of-concept data from our early pipeline that explore a new mechanism of action maturation inhibitor. We look forward to sharing these findings during CROI 2021 with the HIV community.”